Oct 3 (Reuters) -- U.S. health regulators have approved Pfizer Inc's menopause drug Duavee, which is designed to reduce hot flashes with fewer side effects than older hormone-replacement therapies.
The Food and Drug Administration said on Thursday it approved the drug to treat women with moderate to severe menopause symptoms and to prevent post-menopausal osteoporosis, a bone disease which can increase the risk of fractures.
The drug, which Pfizer is developing with Ligand Pharmaceuticals Inc, combines bazedoxifene - which belongs to a class of drugs known as selective estrogen receptor modulators, or SERMS - and conjugated estrogens, which are derived from the urine of pregnant horses and contained in the hormone replacement drug Premarin.
U.S. Census data from 2000 indicate there are about 37.5 million women reaching or currently at menopause, which typically occurs between the ages of 40 and 59, according to the Centers for Disease Control and Prevention.
Read the whole story at Reuters [1]
Earlier on HuffPost50:
References
- ^ Read the whole story at Reuters (www.reuters.com)
- ^ Send us a tip (www.huffingtonpost.com)
- ^ Send us a photo or video (www.huffingtonpost.com)
- ^ Suggest a correction (www.huffingtonpost.com)
0 comments:
Post a Comment